Replies to post #127356 on Biotech Values

[DewDiligence]

Can NVS extend the patent life of Gleevec via this indication (PAH)?

What NVS can do is obtain three years of Hatch-Waxman marketing exclusivity for the new indication, but this doesn’t help ARIA.

Note that the imatinib dose for PAH is likely to be 200mg, which is not one of approved dosage strengths for Gleevec. This is almost certainly intentional.